AI Drug Discovery Stocks Retail Investors Are Watching After Claude Science

Anthropic’s launch of Claude Science has thrown fresh attention on stocks that sit at the intersection of artificial intelligence and drug discovery, where software meets lab science. For investors watching this theme, the question is which companies might gain most from large pharma and biotech groups exploring AI tools for protein modelling, target identification and faster experiments, and which might struggle if regulation tightens. This article picks out 3 stocks from our AI Powered Drug Discovery screener that are directly exposed to the Claude Science news and explains how each could be positioned as this story develops.

Overview: IDEAYA Biosciences is a precision oncology company that uses molecular diagnostics and advanced computational tools, including AI methods, to design targeted cancer drugs for specific genetic profiles, with a pipeline spanning uveal melanoma, small cell lung cancer and other solid tumors. Its programs, such as oral PKC inhibitor darovasertib and multiple antibody drug conjugates, are being tested both alone and in combination with treatments from large pharma partners.

Market Cap: US$3.48b

IDEAYA Biosciences is drawing attention because it sits at the intersection of AI powered drug discovery and targeted cancer medicine, supported by partnerships with groups like Roche, AstraZeneca and Gilead that help validate its platform and share development risk. The company is still loss making, with a recent quarterly net loss of US$98.54 million and funding coming from higher risk external borrowing plus a US$300 million equity raise, so dilution and ongoing cash needs are important watchpoints. At the same time, management is focusing on its MTAP deleted and synthetic lethality programs. Simply Wall St’s DCF suggests the shares trade well below estimated cash flow value, which presents a mix of potential upside and execution risk for investors to weigh.

IDEAYA’s AI powered oncology story, large pharma partnerships and Simply Wall St’s DCF gap raise a clear question: see how the DCF valuation analysis for IDEAYA Biosciences lines up with dilution risk and what the market might be missing

Overview: Personalis is a cancer genomics company that uses AI and advanced sequencing to run ultra sensitive blood and tissue tests, helping drug developers and doctors detect minimal residual disease, monitor treatment response and match patients to therapies and trials.

Operations: Personalis generates about US$64.5 million in revenue from advanced cancer genomic tests for precision oncology and personalized testing, with roughly US$59.1 million coming from the United States and US$5.4 million from other regions.

Market Cap: US$1.44b

Personalis provides direct exposure to AI powered oncology testing at a time when tools like Claude Science are putting fresh focus on data rich drug development. Its NeXT Personal liquid biopsy has recent clinical and regulatory momentum, including expanded MolDX coverage and EU/UK approvals. At the same time, the company remains loss making, carries a very high P/S multiple and is preparing a US$150 million equity raise, so dilution and funding risk are key considerations. For investors willing to accept volatility and reimbursement uncertainty, the mix of AI driven MRD science, pharma partnerships and rapid test adoption raises a broader question about what the current share price is, and is not, pricing in.

Personalis is pairing AI heavy MRD science with a very high P/S and fresh equity plans, so the real story sits in the 1 key reward and 3 important warning signs that could explain what current pricing might be masking

Overview: Exscientia is an Oxford based pharma tech company that uses AI to design and develop small molecule drugs, with a pipeline that includes oncology, inflammation and immunology candidates such as CDK7 inhibitor GTAEXS617 and PKC theta inhibitor EXS4318, supported by collaborations with groups like Merck KGaA, Bristol Myers Squibb and Sanofi.

Operations: Exscientia generates about £17.1 million in revenue from discovering and developing small molecule drug candidates for partners.

Market Cap: US$633.5m

Exscientia sits at the center of the Claude Science story because its entire model is built around AI first drug design, which could become more valuable as pharma companies look for partners that already know how to turn complex models into real clinical candidates. Forecast revenue growth of about 39.8% a year points to strong expectations for its platform, but the company is still unprofitable, has seen earnings decline around 41.2% annually over 5 years, carries a high P/S multiple near 29.7x and relies on higher risk external borrowing. For investors, the tension between that growth outlook, deep pharma collaborations and a history of shareholder dilution is where the real opportunity or downside may lie.

Exscientia’s AI first drug engine is attracting attention, but the missing piece is how expectations, partnerships and past dilution really fit together in one picture, so read the analysis report for Exscientia for the twist investors often overlook

The three AI drug discovery stocks covered here are only a starting point, as the full AI-Powered Drug Discovery screener surfaces 5 more companies with equally compelling narratives that could sit on your watchlist next. Identify and analyze the specific catalysts, funding profiles and AI driven drug discovery angles that matter most to you by filtering these companies inside Simply Wall St so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If Personalis or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Fresh opportunities can move from under the radar to fully priced faster than many investors expect, especially when momentum builds quietly. Scan these curated ideas before the crowd and get in early.

• Spot resilient operators before the next market wobble by sorting through a curated 74 resilient stocks with low risk scores that prioritises balance sheet strength and consistent fundamentals while it still feels overlooked, not crowded.
• Hunt for high quality businesses trading on compressed expectations by using the hand picked 43 high quality undervalued stocks to find companies where sentiment has dropped faster than their fundamentals.
• Ride structural shifts in automation by reviewing the focused 29 robotics and automation stocks packed with companies positioned around robotics, control systems and industrial efficiency while they are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com